Category: Data


PROTECT Series of Clinical Studies Provides Mounting Evidence for Impella Support in High-risk PCI

Looking at the data from the PROTECT Series—PROTECT I1, PROTECT II RCT2, and PROTECT III—William O’Neill, MD, medical director of the Center for Structural Heart Disease at Henry Ford Hospital believes that “the totality of clinical data in favor of Impella supported high-risk PCI allows interventional cardiologists to be confident they are using the optimal … Continue reading “PROTECT Series of Clinical Studies Provides Mounting Evidence for Impella Support in High-risk PCI”

Value of Complete Revascularization in a Single Setting

Dr. Rajan Patel Presents Supporting Data at TCT 2019 “I’m going to talk about some compelling data demonstrating the value of complete revascularization,” Dr. Rajan Patel states as he opens this TCT 2019 presentation, “and give you some provocative data suggesting that complete revascularization in a single setting may be better than staging complete revascularization.” … Continue reading “Value of Complete Revascularization in a Single Setting”

Impella Support and Acute Kidney Injury During High-Risk PCI

Results from the cVAD Study™ on Renal Protection Dr. Michael Flaherty presents data on acute kidney injury (AKI) in patients undergoing high-risk PCI with Impella® support. Dr. Flaherty is director, research-interventional cardiology at Baptist Health Medical Group, Heart and Vascular Center in Louisville, Kentucky. In this presentation, Dr. Flaherty focuses on data from his 2017 … Continue reading “Impella Support and Acute Kidney Injury During High-Risk PCI”

PROTECT III

New PROTECT III Data Demonstrates Impella® Reduces MACCE Compared to IABP Dr. Jeffrey Popma examines the current clinical evidence for Protected PCI with left ventricular support, including new PROTECT III data from an ongoing FDA post-approval study. Dr Popma is director of interventional cardiology clinical services at Beth Israel Deaconess Medical Center in Boston. “I … Continue reading “PROTECT III”

What is Restore EF?

Impact on EF at 60-180 days after high-risk PCI with Impella® support Jason Wollmuth, MD and Thom Dahle, MD, 2 of the principal investigators in the RESTORE EF Study, share their thoughts on the trial with Dr. Seth Bilazarian. “It is an important study that hopefully will provide further depth of knowledge and body of … Continue reading “What is Restore EF?”

New Clinical Publication: Long-Term Outcomes of Complex, High-Risk PCI Patients

Dr. Shon Chakrabarti shares information on a recent publication from the Journal of Interventional Cardiology by Dr. Francesco Burzotta and colleagues on data from the Roma-Verona Registry. This study examined the long-term outcomes of complex high-risk patients with multivessel disease who were considered unsuitable for surgery and received an Impella-supported Protected PCI. Dr. Burzotta and … Continue reading “New Clinical Publication: Long-Term Outcomes of Complex, High-Risk PCI Patients”

Use of Impella® Devices During High-Risk PCI is Associated with Reduced Occurrence of Acute Kidney Injury

Patients undergoing complex coronary revascularization are at risk for periprocedural and postprocedural acute kidney injury (AKI), a complication which correlates with an increased risk of death, major bleeding, and myocardial infarction (MI).1 A reduction in cardiac output and renal hypoperfusion, which in turn leads to a decrease in glomerular filtration rate, may partly explain the increased risk for AKI during high-risk percutaneous coronary intervention (HRPCI).1Currently, there are few published studies which examine the impact of micro-axial percutaneous left ventricular assist devices on AKI in patients undergoing HRPCI. Continue readingUse of Impella® Devices During High-Risk PCI is Associated with Reduced Occurrence of Acute Kidney Injury